

Regulatory Compliance Training Manual for Pharmacy Professionals

Dr. Adetoro Oriaifo, PharmD, MBA, FACHE, 340B ACE, CHCEF

Quantum 5D Consulting | 2026 Edition | Estimated read: 25 minutes

Pharmacy regulatory compliance is not a static checkbox exercise. It is a living discipline that demands continuous education, systematic processes, and organizational commitment. Whether you operate a community pharmacy, a hospital pharmacy, a 340B covered entity, or a compounding facility, the regulatory landscape spans federal agencies, state boards, accreditation bodies, and payer requirements that intersect in complex ways.

This training manual provides pharmacy professionals with a practical, structured overview of the core compliance domains they must master. It is designed for use in staff orientation, annual compliance training, and as a reference document for pharmacists, pharmacy technicians, compliance officers, and organizational leaders.

Table of Contents

1. Overview of the Pharmacy Regulatory Landscape
2. DEA Compliance: Controlled Substances
3. FDA Regulations: Drug Safety and Beyond
4. State Board of Pharmacy Requirements
5. HIPAA Compliance in Pharmacy Settings

- 6. USP Standards: 795, 797, and 800
- 7. Documentation and Record-Keeping Best Practices
- 8. Common Compliance Violations and How to Avoid Them
- 9. Self-Assessment Tools and Audit Checklists
- 10. Training Program Design and Competency Assessment

1. Overview of the Pharmacy Regulatory Landscape

Pharmacy compliance operates across three distinct but overlapping layers of authority. Understanding which body governs what, and where they overlap, is essential to building a compliant operation.

Regulatory Layer	Key Bodies	Primary Focus
Federal	DEA, FDA, CMS, HRSA/OPA, HHS/OCR, FTC	Controlled substances, drug safety, Medicare/Medicaid, 340B, privacy, advertising
State	State Boards of Pharmacy, State Health Departments, Medicaid Agencies	Licensing, scope of practice, inspections, Medicaid compliance
Accreditation & Voluntary	TJC, URAC, ACHC, PCAB, NABP	Quality standards, specialty pharmacy accreditation, compounding accreditation

Where the Layers Intersect

A single pharmacy activity can trigger obligations under multiple layers simultaneously. Dispensing a Schedule II controlled substance, for example, involves DEA registration and record-keeping requirements, state prescription monitoring program (PMP/PDMP) reporting, FDA labeling regulations, state board dispensing standards, and potentially CMS conditions of participation if the patient is a Medicare or Medicaid beneficiary.

Key Takeaway: Never assume compliance with one layer satisfies another. Federal law sets the floor; state law often imposes stricter requirements. When federal and state rules conflict, the more restrictive standard generally applies.

The Compliance Hierarchy in Practice

When navigating conflicting requirements, pharmacy professionals should apply this hierarchy:

1. If state law is more restrictive than federal law, follow state law.
2. If federal law is more restrictive than state law, follow federal law.
3. If an accreditation standard exceeds both, follow the accreditation standard (if you hold that accreditation).
4. If organizational policy is more restrictive than any external requirement, follow organizational policy.

2. DEA Compliance: Controlled Substances

The Drug Enforcement Administration (DEA) enforces the Controlled Substances Act (CSA), which classifies drugs into five schedules based on their potential for abuse, accepted medical use, and safety profile. Every pharmacy that handles controlled substances must maintain active DEA registration and adhere to strict ordering, storage, dispensing, and record-keeping requirements.

Controlled Substance Schedules

Schedule	Abuse Potential	Medical Use	Examples
I	High	No currently accepted use	Heroin, LSD, MDMA, peyote
II	High	Accepted with severe restrictions	Oxycodone, fentanyl, methylphenidate, amphetamine salts
III	Moderate	Accepted	Buprenorphine, testosterone, ketamine, acetaminophen with codeine
IV	Low	Accepted	Alprazolam, zolpidem, tramadol, diazepam
V	Lowest	Accepted	Pregabalin, cough preparations with codeine (limited quantities)

Ordering and Procurement

Schedule II substances must be ordered using DEA Form 222 (triplicate) or through the Controlled Substance Ordering System (CSOS), which uses digital certificates for electronic ordering. The CSOS process requires:

- A valid CSOS digital certificate issued by the DEA to an authorized individual
- Electronic signature applied to each order
- Records retained for a minimum of two years
- Ability to produce records for DEA inspection within 48 hours of request

Schedule III-V substances may be ordered through standard purchase orders but must still be tracked and reconciled.

Storage Requirements

DEA regulations require that controlled substances be stored in a securely locked, substantially constructed cabinet or safe, or dispersed among non-controlled inventory in a manner that obstructs theft or diversion. Schedule II substances must be stored in a locked safe or vault. Access must be limited to authorized personnel, and access logs should be maintained.

Record-Keeping and Inventory

- **Biennial inventory:** A complete inventory of all controlled substances must be conducted every two years from the date of initial inventory. Many pharmacies conduct annual inventories as a best practice.
- **Perpetual inventory:** Strongly recommended for Schedule II substances. Many state boards mandate perpetual inventory for C-II drugs.
- **Discrepancy reporting:** Significant losses or thefts must be reported to the DEA using Form 106.
- **Destruction:** Expired or unwanted controlled substances must be destroyed using a DEA-authorized reverse distributor or through a DEA-authorized take-back event.

CSOS Compliance Tip

Ensure your pharmacy has at least two individuals with active CSOS certificates. If your sole certificate holder leaves the organization, you cannot order Schedule II substances until a new certificate is issued, which can take weeks.

3. FDA Regulations: Drug Safety and Beyond

The Food and Drug Administration (FDA) oversees drug safety, efficacy, labeling, advertising, manufacturing, and distribution. Pharmacy professionals must understand several key FDA programs and regulatory frameworks.

Drug Safety and Recalls

The FDA classifies drug recalls into three classes:

Class	Risk Level	Description	Required Action
Class I	Most serious	Reasonable probability of serious adverse health consequences or death	Immediate removal from shelves; patient notification
Class II	Moderate	May cause temporary or medically reversible adverse health consequences	Removal; assess patient impact
Class III	Low	Not likely to cause adverse health consequences	Removal; routine documentation

Every pharmacy must have a written recall procedure that includes monitoring FDA recall notices (MedWatch, FDA Enforcement Reports), quarantining affected products immediately upon notification, documenting lot numbers and quantities affected, notifying patients who received recalled products (Class I), and returning products according to manufacturer instructions.

REMS Programs

Risk Evaluation and Mitigation Strategies (REMS) are FDA-required risk management programs for medications with serious safety concerns. Pharmacies must comply with REMS requirements, which may include:

- **Medication Guides:** Patient-friendly information that must be dispensed with each prescription
- **Communication Plans:** Healthcare provider education and outreach
- **Elements to Assure Safe Use (ETASU):** Prescriber certification, patient enrollment, pharmacy certification, and dispensing restrictions

Common REMS programs that pharmacies encounter include iPLEDGE (isotretinoin), Clozapine REMS, Opioid Analgesic REMS, and TIRF REMS (transmucosal immediate-release fentanyl).

Compounding: 503A vs. 503B

The Drug Quality and Security Act (DQSA) established two distinct frameworks for compounding:

Feature	Section 503A (Traditional)	Section 503B (Outsourcing Facility)
Registration	State Board of Pharmacy license	FDA registration required
Prescription requirement	Must have patient-specific prescription	May compound without patient- specific prescription
Distribution	Primarily intrastate	May distribute interstate
cGMP compliance	Exempt from cGMP	Subject to cGMP requirements

Feature	Section 503A (Traditional)	Section 503B (Outsourcing Facility)
FDA inspection	Not routinely inspected by FDA	Subject to FDA inspection
Adverse event reporting	Not required to report to FDA	Must report adverse events to FDA
Product labeling	Patient-specific labeling	Must include lot number, BUD, quantity

Key Takeaway: A traditional compounding pharmacy (503A) that begins shipping large volumes of product across state lines without patient-specific prescriptions is operating outside its legal authority and risks FDA enforcement action. Understand which framework applies to your operation.

4. State Board of Pharmacy Requirements

State Boards of Pharmacy are the primary regulatory authority for day-to-day pharmacy operations. While requirements vary by state, certain core obligations are universal.

Licensing and Registration

- **Pharmacy license:** The physical location must hold a current, valid pharmacy permit/license.
- **Pharmacist license:** Each pharmacist must hold a current license in the state where they practice, including completion of continuing education (CE) requirements.
- **Technician registration/certification:** Requirements vary widely. Some states require national certification (PTCB or ExCPT); others require state-specific

registration.

- **Pharmacist-in-Charge (PIC):** Every pharmacy must designate a PIC who is responsible for compliance with all pharmacy laws and regulations.

Inspections

State boards conduct both routine and for-cause inspections. Common inspection focus areas include:

- Controlled substance inventory accuracy and security
- Prescription filing systems and record retention
- Proper storage conditions (temperature, light, humidity)
- Staffing ratios (pharmacist-to-technician ratios vary by state)
- Compounding practices and documentation
- Patient counseling compliance
- Expired medication removal from active stock

Scope of Practice Considerations

Scope of practice for pharmacists and technicians has been expanding rapidly. Many states now authorize pharmacists to prescribe or furnish certain medications (hormonal contraceptives, naloxone, tobacco cessation products), administer vaccines across broader age ranges, perform point-of-care testing, and enter into collaborative practice agreements with physicians. Pharmacy staff must understand the specific scope of practice laws in every state where they are licensed and practice accordingly.

Multistate Compliance

Organizations operating pharmacies in multiple states must maintain state-specific compliance policies. A practice that is legal in one state may be prohibited in

another. Develop state-specific addenda to your compliance manual rather than relying on a single national policy.

5. HIPAA Compliance in Pharmacy Settings

Pharmacies are covered entities under the Health Insurance Portability and Accountability Act (HIPAA). This means they must comply with the Privacy Rule, Security Rule, and Breach Notification Rule.

Protected Health Information (PHI) in Pharmacy

PHI in a pharmacy setting includes prescription records, medication histories, patient demographic information, insurance and billing records, clinical notes and consultations, and any communication about a patient's health status or treatment. PHI exists in multiple forms: paper prescriptions, electronic health records, verbal communications at the counter, faxes, and voicemails.

Minimum Necessary Standard

Pharmacy staff must limit the use and disclosure of PHI to the minimum amount necessary to accomplish the intended purpose. This applies to internal access (limiting system access based on job role), external disclosures (providing only the specific data requested by a payer or provider), and verbal communications (lowering voices at the counter, using private consultation areas).

Breach Notification Requirements

Breach Size	Notification To	Timeline
Fewer than 500 individuals	Affected individuals + HHS (annual log)	Individual notification within 60 days of discovery; HHS within 60 days of calendar year end
500 or more individuals	Affected individuals + HHS + prominent media	All notifications within 60 days of discovery

Common HIPAA Pitfalls in Pharmacy

- Leaving prescription labels visible to other customers at the pick-up counter
- Discussing patient information in areas where other patients can overhear
- Sending PHI via unencrypted email or text message
- Failing to log out of pharmacy management systems when stepping away
- Improper disposal of prescription labels, printouts, or patient paperwork
- Sharing login credentials among staff members

Key Takeaway: HIPAA violations can result in penalties ranging from \$100 to \$50,000 per violation, with an annual maximum of \$1.5 million per violation category. Criminal penalties can include fines up to \$250,000 and imprisonment. Train every staff member, not just pharmacists.

6. USP Standards: 795, 797, and 800

The United States Pharmacopeia (USP) publishes enforceable standards for compounding and hazardous drug handling. Three chapters are particularly critical for pharmacy operations.

USP Chapter	Subject	Applies To	Key Focus Areas
<795>	Nonsterile Compounding	All pharmacies performing nonsterile compounding	Personnel training, facility requirements, master formulation records, beyond-use dating, quality assurance
<797>	Sterile Compounding	All facilities preparing compounded sterile preparations (CSPs)	Cleanroom design, ISO classifications, garbing, aseptic technique, environmental monitoring, BUD assignment
<800>	Hazardous Drugs	All entities handling hazardous drugs (HD)	Assessment of risk, engineering controls, PPE, deactivation/decontamination, spill management, medical surveillance

USP <795> Key Requirements

- **Master Formulation Record (MFR):** Required for every compounded preparation, documenting ingredients, quantities, equipment, mixing procedure, and beyond-use date (BUD).
- **Compounding Record:** A record created for each batch documenting actual ingredients used, personnel involved, date compounded, and assigned BUD.
- **Beyond-Use Dating:** Must be assigned based on stability data, professional literature, or USP default criteria. The pharmacist must document the rationale.
- **Personnel Training:** All compounding personnel must demonstrate competency before compounding independently and undergo periodic reassessment.

USP <797> Key Requirements

- **Cleanroom Classifications:** ISO 5 (primary engineering control), ISO 7 (buffer area), ISO 8 (ante-area). Air quality must be verified through viable and nonviable environmental monitoring.
- **Garbing:** Specific garbing procedures must be followed in defined order, including shoe covers, head cover, face mask, hand hygiene, and sterile gown and gloves.
- **Media Fill Testing:** Personnel must successfully complete media fill tests (aseptic technique validation) before compounding CSPs and at regular intervals thereafter.
- **BUD Categories:** BUDs are assigned based on compounding conditions (category 1 vs. category 2) and sterility testing.

USP <800> Key Requirements

- **Assessment of Risk:** Facilities must maintain a list of hazardous drugs (HDs) handled and perform a risk assessment for each activity involving HDs.
- **Engineering Controls:** Containment primary engineering controls (C-PECs) and containment secondary engineering controls (C-SECs) are required for HD manipulation.
- **Personal Protective Equipment:** Chemotherapy gloves tested per ASTM D6978, gowns, eye/face protection, and respiratory protection as indicated.
- **Spill Management:** Written spill procedures, spill kits in all HD handling areas, and trained staff to manage spills.
- **Medical Surveillance:** A medical surveillance program must be offered to all personnel who handle HDs.

Enforcement Note

USP standards are enforceable in most states through state board of pharmacy regulations that incorporate USP chapters by reference. Even where not explicitly

adopted, courts and regulators often cite USP standards as the expected standard of care. Treat USP compliance as mandatory, not aspirational.

7. Documentation and Record-Keeping Best Practices

In regulatory compliance, the rule is simple: if it is not documented, it did not happen. Comprehensive, organized record-keeping is both a regulatory requirement and the primary defense in any audit or investigation.

Critical Records and Retention Periods

Record Type	Minimum Retention	Governing Authority
Prescription records	2-7 years (varies by state)	State Board of Pharmacy
DEA controlled substance records	2 years	DEA (21 CFR 1304)
HIPAA-related documentation	6 years	HHS/OCR
Compounding records (USP)	1 year beyond BUD or 3 years (state-dependent)	State BOP / USP
Employee training records	Duration of employment + 3 years	OSHA / State BOP

Record Type	Minimum Retention	Governing Authority
Temperature logs	3 years	State BOP / accrediting body
340B records	5 years	HRSA/OPA

Documentation Best Practices

1. **Standardize templates:** Use consistent forms and templates for all compliance documentation. Eliminate ad hoc record-keeping.
2. **Date and sign everything:** Every compliance record should include the date, time, printed name, and signature of the responsible individual.
3. **Never alter retrospectively:** If a correction is needed, draw a single line through the error, note the correction, date it, and initial it. Never use white-out or overwrite entries.
4. **Centralize storage:** Maintain a single, organized location (physical or electronic) for all compliance records. Avoid scattered files across multiple systems.
5. **Automate where possible:** Use electronic systems for temperature monitoring, controlled substance counts, and training tracking. Automated systems reduce human error and create audit trails.
6. **Conduct periodic reviews:** Assign a staff member to review records monthly for completeness, accuracy, and timeliness.

Regulatory auditors do not give credit for good intentions. They evaluate documentation. Build your compliance program around creating clear, contemporaneous, complete records of every required activity.

8. Common Compliance Violations and How to Avoid Them

Understanding the most frequently cited violations helps pharmacy teams prioritize their compliance efforts. The following table summarizes violations that pharmacy regulatory bodies identify most often during inspections and audits.

Violation	Regulatory Domain	Prevention Strategy
Controlled substance inventory discrepancies	DEA / State BOP	Perpetual inventory system; monthly random audits; two-person counts
Expired medications on active shelves	State BOP / FDA	Monthly expiration checks; FEFO stock rotation; automated alerts from pharmacy system
Inadequate patient counseling documentation	State BOP / OBRA '90	Document offer to counsel and actual counseling provided; use standardized workflow prompts
Temperature excursion without documentation	State BOP / USP	Continuous digital temperature monitoring with automatic alerts; written excursion SOPs
Inadequate compounding records	State BOP / USP <795> / <797>	Enforce completion of compounding records before product release; supervisor review
Failure to report controlled substance losses	DEA	Immediate investigation protocol; DEA Form 106 filing within defined timeframe

Violation	Regulatory Domain	Prevention Strategy
PHI exposure (verbal, visual, or electronic)	HIPAA	Privacy screens; counter shields; encrypted communications; workstation timeout policies
Outdated or incomplete policies and procedures	All domains	Annual P&P review cycle with documented sign-off by PIC and compliance officer
Lapsed staff credentials or training	State BOP / OSHA	Credential tracking system with 90-day advance alerts; block scheduling for unlicensed staff
Hazardous drug handling without proper PPE	USP <800> / OSHA	PPE readily available in all HD areas; competency validation; direct observation audits

Key Takeaway: Most compliance violations are preventable with systematic processes. The common thread is not a lack of knowledge but a lack of consistent execution. Build systems that make the compliant action the default action.

9. Self-Assessment Tools and Audit Checklists

Regular self-assessment is the most effective way to identify and correct compliance gaps before a regulatory inspection reveals them. The following checklists are designed for monthly or quarterly internal audits.

Monthly Controlled Substance Audit Checklist

Audit Item	Compliant?	Notes / Corrective Action
☐ DEA registration current and posted		
☐ Schedule II perpetual inventory reconciled		
☐ Random C-II count matches perpetual record		
☐ DEA 222 forms filed and accounted for		
☐ CSOS certificates current for authorized staff		
☐ Controlled substance safe/cabinet secure		
☐ Access log reviewed for anomalies		
☐ Expired controlled substances quarantined		
☐ Destruction records complete (if applicable)		
☐ PDMP reporting current per state requirements		

Quarterly HIPAA Compliance Checklist

Audit Item	Compliant?	Notes / Corrective Action
☐	Notice of Privacy Practices posted and available	
☐	All staff completed HIPAA training (within 12 months)	
☐	Business Associate Agreements current with all vendors	
☐	Workstation screens not visible to public	
☐	Automatic workstation lock-out enabled (15 min or less)	
☐	Prescription bag labels not visible at pick-up window	
☐	PHI disposal process followed (shredding/secure bins)	
☐	No shared login credentials in use	
☐	Incident/breach log reviewed and current	
☐	Security risk assessment completed (annual)	

Annual Comprehensive Compliance Review

Audit Item	Compliant?	Notes / Corrective Action
☐	All pharmacy licenses and permits current	
☐	All pharmacist and technician licenses verified	
☐	Continuing education records on file for all staff	
☐	Policies and procedures reviewed and updated	
☐	Biennial controlled substance inventory completed	
☐	Compounding competency assessments current	
☐	USP <800> hazardous drug list updated	
☐	Temperature monitoring equipment calibrated	
☐	Emergency preparedness plan reviewed	
☐	HIPAA security risk assessment completed	

Audit Item	Compliant?	Notes / Corrective Action
☐ Recall response procedure tested		
☐ Employee training matrix complete and current		

10. Training Program Design and Competency Assessment

A compliance training program is only as good as its design, delivery, and follow-through. Effective pharmacy compliance training must be role-specific, competency-based, and documented.

Training Program Framework

Component	Description	Frequency
New hire orientation	Comprehensive overview of all compliance domains; policies and procedures review; hands-on demonstrations	Within first 30 days of hire
Annual refresher training	Updates on regulatory changes; review of incident trends; reinforcement of core requirements	Annually (calendar or anniversary date)
Topic-specific training	Deep dives on high-risk areas (controlled substances, compounding, HIPAA,	As needed based on risk assessment

Component	Description	Frequency
	hazardous drugs)	
Regulatory update training	New laws, rule changes, revised USP chapters, new REMS programs	Within 30 days of effective date
Corrective action training	Targeted retraining following an identified compliance gap or incident	Immediately upon identification

Competency Assessment Methods

Training without assessment is awareness, not competency. Use multiple assessment methods to validate that staff can apply their knowledge:

- **Written assessments:** Post-training quizzes with a minimum passing score (80% is a common threshold). Require remediation and retesting for those who do not pass.
- **Direct observation:** Supervisors observe staff performing critical compliance tasks (controlled substance counts, aseptic technique, proper garbing, patient counseling) and document competency using standardized checklists.
- **Simulation exercises:** Tabletop exercises for recall response, breach notification, DEA theft/loss reporting, and hazardous drug spill management.
- **Practical demonstrations:** Staff demonstrate proper technique for compounding procedures, PPE donning/doffing, and controlled substance reconciliation.
- **Annual competency review:** Comprehensive reassessment combining written testing, direct observation, and review of any compliance incidents involving the individual.

Training Documentation Requirements

For every training event, document the following:

- Training topic and specific content covered
- Date, time, and duration of training
- Trainer name and qualifications
- Attendee sign-in with printed name and signature
- Assessment results (if applicable)
- Remediation plan (if assessment not passed)
- Follow-up date for reassessment (if applicable)

Building a Culture of Compliance

The most effective compliance programs go beyond training events. They embed compliance into daily operations through standard work, visual management (posted reminders, color-coded labels), peer accountability, and leadership modeling. When the Pharmacist-in-Charge and pharmacy leadership visibly prioritize compliance, staff follow. When leadership treats compliance as an obstacle, violations become inevitable.

Tracking and Reporting

Maintain a training matrix that tracks every staff member against every required competency. This matrix should be reviewed monthly and should flag upcoming training due dates at least 90 days in advance. Use the matrix during annual performance reviews to ensure compliance training is tied to performance expectations.

Consider tracking these metrics to measure your compliance training program's effectiveness:

- Percentage of staff current on all required training modules
- Average assessment scores by module

- Number of compliance incidents per quarter (trending over time)
- Time to complete corrective action training following an incident
- Inspection/audit findings trend (decreasing findings indicates program effectiveness)

Compliance is not a destination. It is a continuous process of assessment, training, monitoring, and improvement. The organizations that excel at compliance are not the ones with the thickest policy manuals. They are the ones with the most consistent daily execution.

About the Author

Dr. Adetoro Oriaifo, PharmD, MBA, FACHE, 340B ACE, CHCEF is the founder of Quantum 5D Consulting. With deep expertise in 340B program management, FQHC operations, and pharmacy compliance, Dr. Oriaifo has helped dozens of healthcare organizations navigate complex regulatory environments and maximize their 340B program value. She holds a Doctor of Pharmacy from the University of Maryland School of Pharmacy and an MBA with a focus on healthcare administration.

Quantum 5D Consulting

quantum5dconsulting.com | info@quantum5dconsulting.com | (410) 921-3989

© 2026 Quantum 5D Consulting. All rights reserved.

This document is provided for educational and training purposes. It does not constitute legal advice.

Organizations should consult qualified legal counsel for compliance guidance specific to their jurisdiction and operations.